153 related articles for article (PubMed ID: 17939752)
1. Application of PatchXpress planar patch clamp technology to the screening of new drug candidates for cardiac KCNQ1/KCNE1 (I Ks) activity.
Trepakova ES; Malik MG; Imredy JP; Penniman JR; Dech SJ; Salata JJ
Assay Drug Dev Technol; 2007 Oct; 5(5):617-27. PubMed ID: 17939752
[TBL] [Abstract][Full Text] [Related]
2. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
3. Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride.
Zeng H; Penniman JR; Kinose F; Kim D; Trepakova ES; Malik MG; Dech SJ; Balasubramanian B; Salata JJ
Assay Drug Dev Technol; 2008 Apr; 6(2):235-41. PubMed ID: 18471077
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
[TBL] [Abstract][Full Text] [Related]
5. Action potential clamp and mefloquine sensitivity of recombinant 'I KS' channels incorporating the V307L KCNQ1 mutation.
El Harchi A; McPate MJ; Zhang YH; Zhang H; Hancox JC
J Physiol Pharmacol; 2010 Apr; 61(2):123-31. PubMed ID: 20436212
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiological effects of the anti-cancer drug lapatinib on cardiac repolarization.
Lee HA; Kim EJ; Hyun SA; Park SG; Kim KS
Basic Clin Pharmacol Toxicol; 2010 Jul; 107(1):614-8. PubMed ID: 20406211
[TBL] [Abstract][Full Text] [Related]
7. Tanshinone IIA: a new activator of human cardiac KCNQ1/KCNE1 (I(Ks)) potassium channels.
Sun DD; Wang HC; Wang XB; Luo Y; Jin ZX; Li ZC; Li GR; Dong MQ
Eur J Pharmacol; 2008 Aug; 590(1-3):317-21. PubMed ID: 18573250
[TBL] [Abstract][Full Text] [Related]
8. Chronic probucol treatment decreases the slow component of the delayed-rectifier potassium current in CHO cells transfected with KCNQ1 and KCNE1: a novel mechanism of QT prolongation.
Taniguchi T; Uesugi M; Arai T; Yoshinaga T; Miyamoto N; Sawada K
J Cardiovasc Pharmacol; 2012 Apr; 59(4):377-86. PubMed ID: 22189896
[TBL] [Abstract][Full Text] [Related]
9. Optimization of Ca(v)1.2 screening with an automated planar patch clamp platform.
Balasubramanian B; Imredy JP; Kim D; Penniman J; Lagrutta A; Salata JJ
J Pharmacol Toxicol Methods; 2009; 59(2):62-72. PubMed ID: 19367686
[TBL] [Abstract][Full Text] [Related]
10. The selective estrogen receptor modulator raloxifene inhibits cardiac delayed rectifier potassium currents and voltage-gated sodium current without QTc interval prolongation.
Liu H; Yang L; Jin MW; Sun HY; Huang Y; Li GR
Pharmacol Res; 2010 Nov; 62(5):384-90. PubMed ID: 20674746
[TBL] [Abstract][Full Text] [Related]
11. Assessing use-dependent inhibition of the cardiac Na(+/-) current (I(Na)) in the PatchXpress automated patch clamp.
Penniman JR; Kim DC; Salata JJ; Imredy JP
J Pharmacol Toxicol Methods; 2010; 62(2):107-18. PubMed ID: 20601018
[TBL] [Abstract][Full Text] [Related]
12. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp.
Dubin AE; Nasser N; Rohrbacher J; Hermans AN; Marrannes R; Grantham C; Van Rossem K; Cik M; Chaplan SR; Gallacher D; Xu J; Guia A; Byrne NG; Mathes C
J Biomol Screen; 2005 Mar; 10(2):168-81. PubMed ID: 15799960
[TBL] [Abstract][Full Text] [Related]
13. Characterization of recombinant human cardiac KCNQ1/KCNE1 channels (I (Ks)) stably expressed in HEK 293 cells.
Dong MQ; Lau CP; Gao Z; Tseng GN; Li GR
J Membr Biol; 2006 Apr; 210(3):183-92. PubMed ID: 16909339
[TBL] [Abstract][Full Text] [Related]
14. Autonomic control of cardiac action potentials: role of potassium channel kinetics in response to sympathetic stimulation.
Terrenoire C; Clancy CE; Cormier JW; Sampson KJ; Kass RS
Circ Res; 2005 Mar; 96(5):e25-34. PubMed ID: 15731462
[TBL] [Abstract][Full Text] [Related]
15. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?
Vigneault P; Kaddar N; Bourgault S; Caillier B; Pilote S; Patoine D; Simard C; Drolet B
J Cardiovasc Pharmacol; 2011 Jun; 57(6):690-5. PubMed ID: 21394035
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp.
Haraguchi Y; Ohtsuki A; Oka T; Shimizu T
BMC Pharmacol Toxicol; 2015 Dec; 16():39. PubMed ID: 26671227
[TBL] [Abstract][Full Text] [Related]
17. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
18. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
Qu Y; Gao B; Fang M; Vargas HM
J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
[TBL] [Abstract][Full Text] [Related]
19. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel.
Sanguinetti MC; Curran ME; Zou A; Shen J; Spector PS; Atkinson DL; Keating MT
Nature; 1996 Nov; 384(6604):80-3. PubMed ID: 8900283
[TBL] [Abstract][Full Text] [Related]
20. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds.
Tao H; Santa Ana D; Guia A; Huang M; Ligutti J; Walker G; Sithiphong K; Chan F; Guoliang T; Zozulya Z; Saya S; Phimmachack R; Sie C; Yuan J; Wu L; Xu J; Ghetti A
Assay Drug Dev Technol; 2004 Oct; 2(5):497-506. PubMed ID: 15671647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
